EA202190125A1 - ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl - Google Patents

ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl

Info

Publication number
EA202190125A1
EA202190125A1 EA202190125A EA202190125A EA202190125A1 EA 202190125 A1 EA202190125 A1 EA 202190125A1 EA 202190125 A EA202190125 A EA 202190125A EA 202190125 A EA202190125 A EA 202190125A EA 202190125 A1 EA202190125 A1 EA 202190125A1
Authority
EA
Eurasian Patent Office
Prior art keywords
axl
pyridopyrimidinone derivatives
pyridopyrimidinone
derivatives
axl inhibitors
Prior art date
Application number
EA202190125A
Other languages
English (en)
Inventor
Дзунг-Хо КИМ
Дзанг-Сик Чой
Хее Киу Ли
Донг-Сик ДЗУНГ
Сунг-Хо Парк
Юнг-геун Чой
Original Assignee
Оскотек Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оскотек Инк. filed Critical Оскотек Инк.
Publication of EA202190125A1 publication Critical patent/EA202190125A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Раскрыты производные пиридопиримидинона и фармацевтические композиции, содержащие их, для применения в качестве ингибитора Axl для лечения заболевания или состояния, опосредованного Axl, такого как множественные типы рака и метастазы. Также раскрыты способы лечения Axl-опосредованного заболевания или состояния путем введения субъекту терапевтически эффективного количества производных пиридопиримидинона.
EA202190125A 2018-06-27 2019-06-26 ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl EA202190125A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690620P 2018-06-27 2018-06-27
PCT/KR2019/007733 WO2020004938A1 (en) 2018-06-27 2019-06-26 Pyridopyrimidinone derivatives for use as axl inhibitors

Publications (1)

Publication Number Publication Date
EA202190125A1 true EA202190125A1 (ru) 2021-05-24

Family

ID=68987456

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190125A EA202190125A1 (ru) 2018-06-27 2019-06-26 ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl

Country Status (16)

Country Link
US (1) US20210275532A1 (ru)
EP (1) EP3814350A4 (ru)
JP (1) JP7200453B2 (ru)
KR (1) KR102698500B1 (ru)
CN (1) CN112351985B (ru)
AU (1) AU2019292207B2 (ru)
BR (1) BR112020026641A2 (ru)
CA (1) CA3103160C (ru)
CL (1) CL2020003340A1 (ru)
EA (1) EA202190125A1 (ru)
IL (1) IL279593A (ru)
MX (1) MX2020013805A (ru)
NZ (1) NZ770629A (ru)
SG (1) SG11202013029UA (ru)
WO (1) WO2020004938A1 (ru)
ZA (1) ZA202100140B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064531T2 (hu) 2018-06-27 2024-04-28 Bristol Myers Squibb Co Szubsztituált naftiridinon vegyületek mint T-sejt aktivátorok

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
MY173494A (en) * 2009-10-29 2020-01-29 Genosco Kinase inhibitors
EP2828259B1 (en) 2012-03-22 2018-08-08 Oscotec, Inc. Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
US9533989B2 (en) * 2012-09-18 2017-01-03 Ziarco Pharma Ltd. Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
WO2017214433A1 (en) * 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors

Also Published As

Publication number Publication date
JP2021528383A (ja) 2021-10-21
US20210275532A1 (en) 2021-09-09
CA3103160A1 (en) 2020-01-02
BR112020026641A2 (pt) 2021-03-30
WO2020004938A1 (en) 2020-01-02
EP3814350A1 (en) 2021-05-05
NZ770629A (en) 2024-07-26
CN112351985B (zh) 2023-12-15
JP7200453B2 (ja) 2023-01-10
KR20210014212A (ko) 2021-02-08
ZA202100140B (en) 2022-07-27
CL2020003340A1 (es) 2021-04-23
IL279593A (en) 2021-03-01
CN112351985A (zh) 2021-02-09
SG11202013029UA (en) 2021-01-28
MX2020013805A (es) 2021-03-09
AU2019292207B2 (en) 2022-06-30
EP3814350A4 (en) 2022-05-04
CA3103160C (en) 2023-03-07
KR102698500B1 (ko) 2024-08-26
AU2019292207A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
EA202190630A1 (ru) Способы комбинированной терапии
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
CR20220207A (es) Compuestos terapéuticos y métodos de uso
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA201692470A1 (ru) Фармацевтические комбинации
EA202090414A1 (ru) Соединения и их применение
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
EA202190153A1 (ru) Составы ингибитора axl/mer
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
MX2021011081A (es) Derivados de nicorandil.
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EA202190452A1 (ru) Ингибиторы cdk8/19